阴性淋巴结数目对根治性远端胃大部切除胃癌患者生存率的影响

研究目的在于评估阴性淋巴结数目对根治性远端胃大部切除胃癌患者预后的长期影响。选择1995－2004年间的634例施行根治性远端胃大部切除手术（R0切除）的胃癌患者。调查手术的长期结果,及阴性淋巴结数目与患者5年生存率之间的关系。患者术后5年生存率为57．6％。根据皮尔森试验,阴性淋巴结的转移数量与取检淋巴结总数呈正相关性（P〈0．001）。     

淋巴结清扫数目对无淋巴结转移胃癌患者预后的影响

目的 探讨胃癌根治术中淋巴结清扫数目对无淋巴结转移患者预后的影响.方法 回顾性分析1995年1月至2004年12月期间221例施行D2根治术、术后经病理证实无淋巴结转移的胃癌患者的临床资料.对本组患者预后因素进行单因素及多因素分析,分析淋巴结清扫数目与术后5年生存率及术后并发症发生率的关系.结果 221例无淋巴结转移胃癌患者术后5年生存率为83.5%.淋巴结清扫数目是影响本组患者预后的独立因素之一.相同浸润深度患者的术后5年生存率有随淋巴结清扫数目的 增加而增高的趋势(P<0.05).淋巴结清扫数目pT1.2期≥15枚、pT3期≥20枚时,患者术后5年生存率较高(P<0.05).本组患者术后并发症发生率为10.8%,淋巴结清扫数目与术后并发症发生率的无显著相关性(P>0.05).结论 淋巴结清扫数目是无淋巴结转移胃癌患者的独立预后因素,应积极争取清扫足够的淋巴结,以提高疗效;合理的淋巴结清扫数目并不增加患者术后并发症的发生率.     

Ⅲ期直肠癌根治术淋巴结清扫总数及阴性淋巴结数与预后的关系

目的 探讨Ⅲ期直肠癌根治术后淋巴结清扫总数及阴性淋巴结数与预后的关系.方法 回顾性分析山东大学齐鲁医院2002—2007年412例Ⅲ期直肠癌根治术患者的临床资料.依淋巴结清扫总数及阴性淋巴结数分为5组,分别为1～6枚组、7～12枚组、13～18枚组、19～24枚组和＞ 24枚组,用Kaplan-Meier法计算生存率,生存率的组间比较采用Log-rank检验并做趋势检验.应用Pearson相关分析法分析淋巴结清扫总数与阴性淋巴结数的相关性.多因素分析采用Cox比例风险模型分析.结果 患者1、3、5年生存率分别为79.9％,59.2％,43.0％.患者术后5年生存率随淋巴结清扫总数及阴性淋巴结数目的增加而升高(20.0％、26.5％、43.9％、54.2％、53.5％,P=0.001;10.3％、34.8％、51.9％、56.8％、70.8％,P=0.000).412例患者共清扫淋巴结7301枚,阴性淋巴结5698枚,淋巴结清扫总数及阴性淋巴结数具有明显相关性(r =0.899,P=0.000).淋巴结清扫总数及阴性淋巴结数为独立预后因素.结论 在Ⅲ期直肠癌根治术中,淋巴结清扫总数及阴性淋巴结数与预后明显相关,在规范化进行根治性手术的前提下,可将淋巴结清扫总数及阴性淋巴结数作为判断预后的辅助指标.     

盆腔侧方淋巴结转移对低位直肠癌预后的影响

目的 探讨盆腔侧方淋巴结转移对低位直肠癌预后的影响.方法 对1994年至2005年行根治性切除联合盆腔侧方淋巴结清扫的176例低位直肠癌患者的资料进行回顾性分析.探讨低位直肠癌患者盆腔侧方淋巴结转移对其预后的影响.结果 全组盆腔侧方淋巴结转移33例(18.8%),其中髂内及直肠中动脉根部淋巴结转移占51.5%,闭孔淋巴结转移占39.4%.年龄≤40岁、浸润型癌、T3-4期、上方淋巴结转移患者的盆腔侧方淋巴结转移率较高(P＜0.05).全组5年生存率为64.1%,TNM分期Ⅰ、Ⅱ、Ⅲ期患者5年生存率分别为94.1%、79.1%、42.1%.癌灶大小、浸润深度、上方淋巴结转移、盆腔侧方淋巴结转移是影响低位直肠癌患者预后的重要因素(P＜0.05).盆腔侧方淋巴结阴性患者5年生存率为73.6%,而侧方淋巴结转移患者为21.4%,两组差异具有统计学意义(P＜0.05).结论 盆腔侧方淋巴结转移是影响低位直肠癌预后的重要因素.     

胃癌根治术血管鞘内、外淋巴结清扫临床结果比较分析

目的 比较血管鞘内、外淋巴结清扫对胃癌患者临床结局的影响.方法 回顾性分析1994年6月至2005年4月外科治疗的759例胃癌患者的临床资料,其中根治性切除627例,并分别采取血管鞘内淋巴结清扫(VLND组,215例)和血管鞘外淋巴结清扫(NVLND组,412例).分析比较两组不同的淋巴结清扫方法的手术时间、术中失血量、外科并发症等资料,并比较分析两组术后生存率差异.结果 根治性切除手术后5年和10年生存率比较:VLND组分别为55.4%和51.2%,NVLND组分别为39.1%和36.8%,两组差异均有统计学意义(P<0.05).VLND组中N0～N2、T2～T4、Ib～Ⅳ期胃癌患者术后5、10年累积生存率均显著高于NVLND组.而术中输血量、手术时间、手术并发症、术后并发症两组差异无统计学意义.结论 对于进展期胃癌患者,血管鞘内淋巴结清扫可提高术后生存率,不增加手术时间和术后并发症,是安全的淋巴结清扫技术.     

进展期胃底贲门癌淋巴结清扫数目对预后的影响

目的探讨D2根治术中淋巴结清扫数目对进展期胃底贲门癌患者的预后和术后并发症发生率的影响。方法总结施行D2根治术的236例进展期胃底贲门癌患者的临床资料,将其清扫淋巴结的数目与术后5年患者的生存率及术后并发症发生率的关系进行分析。结果236例进展期胃底贲门癌患者术后5年生存率为37．5％。相同病期患者的术后5年生存率随着淋巴结清扫数目的增加而增高（P=0．0013）。Ⅱ期患者淋巴结清扫数目超过或等于20枚（P=0．0136）、Ⅲ期超过或等于25枚（P〈0．0001）、Ⅳ期超过或等于30枚（P=0．0002）、整组病例超过或等于15枚（P=0．0024）时生存率高,且差异具有统计学意义。本组术后并发症发生率为15．7％,淋巴结清扫的数目与术后并发症发生率的相关性无统计学意义（P=0．101）。结论进展期胃底贲门癌患者在施行D：根治术时,淋巴结清扫数目与患者预后呈正相关;合理的淋巴结清扫数目并不增加患者术后并发症发生率。     

138例淋巴结转移阴性胃癌患者的预后因素分析

目的探讨淋巴结转移阴性胃癌患者的预后影响因素。方法回顾性分析天津医科大学附属肿瘤医院2000—2005年间接受根治性胃切除手术治疗．且术后病理证实为淋巴结转移阴性的138例胃癌患者的临床资料,并对预后影响因素进行单因素和多因素分析。结果本组患者5年生存率为62．4％。单因素分析结果显示,肿瘤大小、肿瘤部位、分化程度、浸润深度、胃切除方式、Lauren分型与患者预后有关（P〈0．05）;多因素分析结果显示,肿瘤大小、分化程度和浸润深度是影响预后的独立因素（P〈0．05）。结论对于接受根治性手术治疗的淋巴结转移阴性的胃癌患者,肿瘤大小、肿瘤分化程度及是否浸润浆膜是评估预后的重要指标。     

侧方淋巴结清扫对进展期低位直肠癌预后的影响

目的 应用治疗指数(therapeutic index,TX)(TX=肿瘤相关5年生存率×区域淋巴结转移的概率)评估侧方淋巴结清扣对于改善进展期低位直肠癌预后的价值.方法 回顾性分析直肠癌行根治性切除+全直肠系膜切除+侧方淋巴结清扫的96例进展期低位直肠癌患者的临床资料.结果 进展期低位直肠癌直肠系膜淋巴结、直肠上动脉旁淋巴结、肠系膜下动脉旁淋巴结和侧方淋巴结转移率分别为21%(20/96),13%(12/96),10%(10/96)和15%(14/96).检出直肠系膜淋巴结、直肠上动脉旁淋巴结、肠系膜下动脉旁淋巴结和侧方淋巴结转移阳性的进展期低位直肠癌患者5年生存率分别为35%,25%,20%和36%.TX:清扫直肠系膜淋巴结和侧方淋巴结的TX分别为7.4和5.4,明显高于清扫直肠上动脉和肠系膜下动脉旁淋巴结的3.3和2.0.侧方淋巴结转移阳性者术后局部复发率为64%(9/14),TX明显高于侧方淋巴结转移阴性者的11%(9/82)(x2=22.308/P=0.000).Kaplan-Meier生存分析显示,侧方淋巴结转移阳性患者平均生存期为(38.0±6.7)个月(95%置信区间:24.8～51.2个月),明显短于侧方淋巴结转移阴性的(80.9±2.1)个月(95%置信区间:76.7～85.1个月),两者差异有统计学意义. 结论侧方淋巴结清扫可降低进展期低位直肠癌根治性切除术后局部复发率以及改善预后.除全直肠系膜切除外,进展期低位直肠癌术中还应进行侧方淋巴结清扫.     

纳米碳与吲哚菁绿导航腹腔镜胃癌根治术淋巴结清扫的对比性研究

目的对比纳米碳与吲哚菁绿(ICG)在腹腔镜胃癌根治术淋巴结清扫方面的优劣性。方法回顾性分析2016年1月至2019年12月接受腹腔镜胃癌根治术的167例患者资料,根据所使用的示踪剂种类,分为纳米碳组130例、ICG组37例,应用GraphPad Prism 8.0统计软件进行分析,围术期指标及淋巴结清扫数目等计量资料以(±s)表示,采用独立t检验;术后并发症、二次手术率等计数指标比较采用χ²检验,P<0.05为差异有统计学意义。结果两种示踪剂对不同病理分期胃癌的淋巴结清扫效果差异无统计学意义。在各种胃癌根治术式中,淋巴结分拣均有助于提高淋巴结总检出数。纳米碳组较ICG组更有助于提高根治性全胃切除术第5站淋巴结的清扫数目(P=0.02)、根治性近端胃切除术第1站淋巴结的清扫数目(P=0.03)以及根治性远端胃淋巴结的总清扫数目(P=0.03)。在提高淋巴结检出率方面,两种示踪剂差异无统计学意义。结论纳米碳与吲哚菁绿在不同病理分期中的总体淋巴结清扫效果差异无统计学意义。无论使用何种示踪剂,均提倡淋巴结分拣。纳米碳较吲哚菁绿更有助于提高根治性全胃第5站淋巴结的清扫数、根治性近端胃第1站淋巴结的清扫数以及根治性远端胃淋巴结的总清扫数目。     

胃周转移淋巴结数对胃癌患者预后评估的价值

目的寻找适用于胃癌术后患者预后比较的简单指标。方法选取1999-2005年间在复旦大学附属中山医院胃肿瘤组接受根治性手术治疗的148例患者的病例资料进行总结,分析胃周淋巴结转移情况及其与患者预后的关系。结果148例患者3年累计总生存率为62．8％,生存率随胃周转移淋巴结数增加而下降。当胃周转移淋巴结数超过6枚时,3年生存率降至15．4％,与全组3年总生存率比较,差异有统计学意义（P〈0．01）。胃周转移淋巴结数与总阳性淋巴结数存在线性关系（r=0．94,P〈0．01）,但与总切除淋巴结数不存在线性关系（r=0．18,P=0．2）。结论胃周转移淋巴结是一个简单有效判断胃癌术后患者预后的指标。胃周转移淋巴结对淋巴结切除技术要求低,可用于比较不同地区间胃癌术后患者的预后。     

腹腔镜辅助胃癌根治术淋巴结清扫效果的临床对照研究

目的 探讨腹腔镜辅助胃癌根治术中淋巴结清扫的可行性及临床效果.方法 2007年1月至2010年5月,对934例胃癌患者施行根治性手术(RO切除),其中行腹腔镜手术患者(腹腔镜组)506例,行开腹手术患者(开腹组)428例.对比两组患者淋巴结清扫数目的 差异,并分析两组淋巴结清扫数目与术后并发症发生率的关系.结果 全部患者平均淋巴结清扫数目为(29±10)枚/例,两组平均淋巴结清扫数目相似(P＞0.05),但腹腔镜组No.7、8组淋巴结清扫数目明显多于开腹组(P＜0.05).按浸润深度分层分析,除pT3期腹腔镜组平均淋巴结清扫数目多于开腹组外,pT1-2期差异无统计学意义(P＞0.05);按淋巴结清扫范围和胃切除方式分层分析,腹腔镜组平均淋巴结清扫数目均与开腹组相当(P＞0.05);按手术时期分层分析,≤50例腹腔镜组平均淋巴结清扫数目少于开腹组(P＜0.05),51～100例和≥101例则与开腹组相当(P＞0.05).腹腔镜组并发症发生率为11.1%,明显低于开腹组的20.1%,但两组淋巴结清扫数目与术后并发症的相关性均无统计学意义(P＞0.05).结论 随着腹腔镜外科医师技术逐渐成熟,腹腔镜胃癌根治手术能够达到与开腹手术相当的淋巴结清扫效果;合理增加腹腔镜辅助胃癌根治术的淋巴结清扫数目不会增加术后并发症发生率.

Abstract：

Objective To explore the feasibility and efficacy of laparoscopy assisted radical gastrectomy on lymph node(LN)dissection for gastric cancer and to compare it with open gastrectomy.Methods The clinical data of 934 patients with gastric cancer underwent radical resection from January 2007 to May 2010 were analyzed retrospectively. Among the patients, 506 cases received laparoscopy assisted gastrectomy(LAG group)and 428 cases received open gastrectomy(OG group). The number of retrieved LNs and the survival curve between the two groups was compared. Then, the relations between the number of dissected LNs and postoperative morbidity were analyzed. ResultsFor all patients, the mean number of dissected LNs was 29±10, there was no significantly differences between LAG group and OG group(P＜0.05). While the number of the retrieved No. 7, 8 LNs in LAG group were significantly more than those in OG group. No significant differences was found in the number of dissected LNs for the pT1-2stages tumors between the two groups, but significantly greater number of LNs was harvested by LAG group in pT3 stage(P＜0. 05). No significant differences were found in the number of dissected LNs in different gastrectomy types or extents of LN dissection between the two groups. In the first 50 cases, there were less dissected LNs in LAG group than that in OG group, while 51 cases later, there was no significantly differences in number of dissected LNS between the two groups(P＞0.05). The postoperative morbidity of LAG group and OG group was 11.1% and 20. 1%, respectively(P ＜0.05), but there was no significant correlations between the number of dissected LNs and postoperative morbidity in both groups. Conclusions With the improvement in surgical skills, laparoscopy-assisted radical gastrectomy with lymph node dissection is a safe and feasible procedure, and it is oncologically compatible with open gastrectomy. Suitable increment of dissected LN count would not increase the postoperative complication rate.     

Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage

Background Advanced, but potentially still curable gastric cancer (stages IIIA, IIIB, or stage IV M0) is associated with very high recurrence rates after gastrectomy. The value of an extended lymph node dissection (ELND) remains unclear in this setting. Methods A resected gastric cancer data set was created through structured queries to the SEER 1973–2000 database. Relationships between the number of lymph nodes (LNs) examined and survival outcomes were analyzed for the stage subgroups characterized by the N categories N2 or N3, and transmural tumor extension (T categories T2b or T3). Results The study group encompassed 1,377 patients, including T2b/3N2 (n = 1,076) and T2b/3N3 stage subgroups (n = 301). Total LN count (or number of negative LNs examined; P < 0.0001), number of positive LNs (P < 0.0001), age (P < 0.0001), primary site (P = 0.0002), T category (P = 0.0271), race (P = 0.0301) and gender (P = 0.0261) were independent prognostic survival predictors. A cut point analysis yielded the ability to detect significant survival differences for LN numbers up to 30 (N2) or up to 40 (N3), always in favor of the higher number of LNs examined. Best long-term survival outcomes were observed with negative LN counts of more than 15 (N2) or more than 20 (N3). Conclusions Even in transmural or serosa-positive gastric cancer with advanced nodal involvement, more extensive LN dissection and analysis influences survival. Stage-based survival prediction depends on total LN number and number of negative LNs. The mechanism remains uncertain, but is not limited to stage migration. ELND during potentially curative gastrectomy is recommended even for advanced gastric cancer.     

Lymph Node Dissection Impact on Staging and Survival of Extrahepatic Cholangiocarcinomas,Based on U.S. Population Data

Cholangiocarcinomas (CC) frequently demonstrate lymphatic spread. We investigated lymph node (LN) counts after resection of extrahepatic CC and survival based on the SEER 1973–2004 database. Out of 20,068 CC patients, 1,518 individuals were selected based on M0 stage and at least one LN examined. Primary cancer sites included gallbladder (29%), extrahepatic bile ducts (26%), and intrapancreatic/ampullary bile ducts (45%); 42% of patients were LN-positive. The median number of LNs examined was four (range 1–39). Median survival was 37 months for LN-negative and 16 months for LN-positive cancers. Multivariate prognostic variables were the number of positive LNs, primary site, age (all at p < 0.0001), gender (p = 0.002), size (p = 0.005), T category (p = 0.009), and total LN count (or number of negative LNs obtained, p = 0.01). The impact of total LN counts was seen in LN-negative (median survival, 1 vs 10 or more LNs examined: 27 vs 51 months, p = 0.002) and LN-positive disease (10 vs 22 months, p < 0.0001). Survival prediction of extrahepatic CCs is strongly influenced by total LN counts and numbers of negative LNs obtained. Although the resulting incremental benefit is small, dissection and examination of 10 or more LNs should be considered for curative intent resections.     

Clinical Impact of Lymphadenectomy Extent in Resectable Esophageal Cancer

Esophageal cancer (EC) frequently presents with advanced stages and is associated with high recurrence rates after esophagectomy. The value of an extended lymph node dissection (ELND) remains unclear in this setting. An EC data set was created from the Surveillance, Epidemiology, and End-Results 1973–2003 database. Relationships between the number of lymph nodes (LNs) examined and overall survival (OS) were analyzed. From a cohort of 40,129 EC patients, 5,620 individuals were selected. The median age was 65 (range: 11–102), and 75% were men. The median tumor size was 5.0 cm (0.1–30). On multivariate analysis, total LN count (or negative LN count, respectively) was an independent prognostic variable, aside from age, race, resection status, radiation, T category, N category (all at p < 0.0001), and M category (p = 0.0003). Higher total LN count (>30) and negative LN count (>15) categories were associated with best OS and lowest 90-day mortality (p < 0.0001). The numeric LN effect on OS was independent from nodal status or histology. Greater total and negative LN counts are associated with longer EC survival. Although the mechanism remains uncertain, it does not appear to be limited to stage migration. ELND during potentially curative esophagectomy for EC can be supported by the data.     

脾门区血管后方淋巴结清扫在进展期近端胃癌根治术中应用价值研究

目的 探讨进展期近端胃癌行全胃切除并D2淋巴结清扫术时是否需要清扫脾门区血管后方（No.10p）淋巴结。方法 回顾性分析2010年1月至2014年12月间在福建医科大学附属协和医院胃外科接受腹腔镜全胃切除术并D2淋巴结清扫术404例近端胃癌病人资料，其中有行脾门区血管后方淋巴结清扫者68例，称No.10p组，仅行脾门区血管前方淋巴结清扫者336例，称nNo.10p组，对比两组病人淋巴结清扫情况和远期疗效的差异。结果 与nNo.10p组相比，No.10p淋巴结清扫更易出现于较年轻、体重指数（BMI）较小、分散型、脾叶血管分支少和胰尾邻近脾下极的病人（P＜0.05）。两组病人平均淋巴结清扫数目和平均阳性淋巴结数目差异均无统计学意义（P＞0.05）；虽然No.10p组获取的脾门淋巴结数目较多（P＜0.05），而两组脾门淋巴结转移发生率和阳性脾门淋巴结数目均相似（P＞0.05）。生存分析显示，No.10p组与nNo.10p组的远期预后差异无统计学意义（P＞0.05），而且不论脾门淋巴结是否转移，No.10p淋巴结清扫均不能提高病人5年存活率（P＞0.05），并且No.10p淋巴结清扫亦不能提高脾门淋巴结清扫的治疗指数。结论 No.10p淋巴结清扫虽能获得更多的脾门淋巴结，但并不能增加脾门淋巴结转移发生率和阳性淋巴结数目，亦未能提高病人的远期预后；故对于进展期近端胃癌行脾门淋巴结清扫时，可无须常规清扫No.10p淋巴结。     

Clinicopathological Features and Surgical Outcomes of Patients with Remnant Gastric Cancer after a Distal Gastrectomy

Background The incidence of gastric cancer in the remnant stomach after distal gastrectomy is increasing. The aim of this study was to evaluate the clinicopathological features and surgical outcomes of remnant gastric cancer (RGC). Methods We reviewed the medical records of 58 patients who underwent laparotomy for RGC at Seoul National University Hospital between 2000 and 2005. Results The mean interval between the first and second operations was 12.5 years, and the rate of RGC diagnosis by tests included the follow-up program was 41.4%. The 45 RGCs occurring after distal gastrectomy for initial gastric cancer had a shorter interval and were more frequently located at the non-anastomotic site than those following benign lesions (P <0.001 and P = 0.010). Of all patients, 41 (70.7%) underwent, and the overall 3-year survival rate was 62.4%. An early stage of the initial gastric cancer, no symptoms at diagnosis, curative resection, tumor size smaller than 6 cm, and an early TNM stage of the RGC were associated with longer survival; the initial gastric disease, the interval and the location of RGC were not. Conclusion The successful curative resection and an early stage of the RGC led to good outcomes. In considering the different latency periods of the two initial gastric diseases, appropriate follow-up programs should be developed.     

Race and Correlations Between Lymph Node Number and Survival for Patients with Gastric Cancer

Background

There is ongoing debate whether extended lymphadenectomy improves survival in gastric cancer patients who undergo surgical resection. We previously observed that Korean–American patients had the highest overall survival in Los Angeles County. Our objective was to assess lymph node (LN) number and its impact on survival for Korean–American gastric cancer patients.

Methods

We utilized the National Cancer Institute’s Surveillance, Epidemiology, and End Results registry to identify Korean–Americans with gastric adenocarcinoma treated with curative-intent gastrectomy between 1988 and 2008. We grouped patients according to examined LN number (1–15 and 16+) and compared characteristics. We performed similar analysis for white patients.

Results

Out of 982 Korean–American patients with gastric adenocarcinoma, most patients had 1–15 examined LNs (60 %). When we compared LN groups, we observed higher overall survival in the 1–15 group than the 16+ group (5-year survival, 59 % vs 52 %, respectively; p?=?0.04). However, LN number was not prognostic of overall survival on stepwise Cox proportional hazards analysis. In contrast, LN number was prognostic for white patients.

Conclusions

Although examined LN number may impact survival for white patients, outcomes of Korean–American gastric cancer patients were independent of LN number. Our data suggest that survival of Korean–American gastric cancer patients are comparable with outcomes from East Asian hospitals and may be independent of surgical technique.     

One-Step Nucleic Acid Amplification (OSNA) for the Application of Sentinel Node Concept in Gastric Cancer

Purpose

This study was designed to apply safely the sentinel node navigation surgery (SNNS) to the malignancies, an accurate and prompt intraoperative diagnosis of SN is essential, and micrometastasis has been frequently missed by conventional frozen sections. Recently, a novel molecular-based rapid diagnosis for the lymph node (LN) metastases has been developed using (OSNA) in breast cancer, which takes approximately 30 min to obtain a final result. We evaluated the efficacy of OSNA in terms of the intraoperative diagnosis of LN metastasis in patients with gastric cancer.

Methods

A total of 162 LNs dissected from 32 patients with gastric cancer was included in this study; 45 LNs were pathologically diagnosed as metastatic LNs and 117 LNs were negative. The LNs were bisected; halves were examined with H&;E stain, and the opposite halves were subjected to OSNA analyses of CK19 mRNA. The CK19 mRNA expression was examined in the positive or negative metastatic LNs, and the correlation between the tumor volume and CK19 mRNA expression in the metastatic LNs was examined.

Results

The CK19 mRNA expressions in the positive metastatic LNs were significantly higher than those of negative LNs. When 250 copies/μl was set as a cutoff value, the concordance rate was 94.4%, the sensitivity was 88.9%, and the specificity was 96.6%. The OSNA expression was significantly correlated with the estimated tumor volumes in the metastatic LNs.

Conclusions

The OSNA method is feasible and acceptable for detecting LN metastases in patients with gastric cancer. This should be applied for the intraoperative diagnosis in the SN-navigation surgery in gastric cancer.